345627-80-7

Basic information

• Product Name: N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
• Synonyms: N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide;N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide(BMS-3870032);BMS-3870032;N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide;BMS-387032;4-Piperidinecarboxamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-;N-(5-((5-Tert-Butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide;1-diMethylethyl)-2-oxazolyl]Methyl]thio]-2-thiazolyl]-
• CAS NO: 345627-80-7
• Molecular Formula: C₁₇H₂₄N₄O₂S₂
• Molecular Weight: 380.53
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals. Sulfur & Selenium Compounds;Pharmaceuticals;Inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.;Specific and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.;Inhibitors
• Mol File: 345627-80-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 171-173 °C
• Appearance: /
• Density: 1.288 g/cm³
• Refractive Index: 1.606
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.33±0.70(Predicted)
• CAS DataBase Reference: N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide(345627-80-7)
• EPA Substance Registry System: N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide(345627-80-7)

Safety Data

• Hazardous Substances Data: 345627-80-7(Hazardous Substances Data)

Usage

Description

N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide is a complex organic compound characterized by its unique molecular structure. It is an off-white solid with potential applications in various fields due to its chemical properties and interactions with specific biological targets.

Uses

Used in Pharmaceutical Industry:
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide is used as a selective inhibitor for Cyclin-dependent Kinase (CDK) 2, 7, and 9. It is particularly effective in cancer therapy, as CDKs are key regulators of cell cycle progression, making them promising targets for cancer treatment. N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide is an ATP-competitive inhibitor with IC50 values of 4, 38, and 62 nM for Cdk9, 2, and 7, respectively. It selectively inhibits these kinases without additional activity against a panel of 190 kinases (IC50s > 1,000 nM). By blocking the cell cycle, inhibiting transcription, and inducing apoptosis in cancer cells, this compound has the potential to be a valuable therapeutic agent in the fight against cancer.
Used in Drug Development:
In the drug development industry, N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide can be utilized as a lead compound for the development of novel therapeutics targeting CDKs. Its selective inhibition of CDK 2, 7, and 9, along with its ability to induce apoptosis by inhibiting the transcription of anti-apoptotic proteins, makes it a promising candidate for further research and development into potential cancer treatments.
Used in Research and Development:
In the research and development sector, N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide can be employed as a tool compound to study the role of CDKs in cell cycle regulation and cancer progression. Its selective inhibition of CDKs allows researchers to investigate the underlying mechanisms of action and potential therapeutic benefits in preclinical models.

references

[1]. tong w.g., chen r., plunkett w., et al. phase i and pharmacologic study of sns-032, a potent and selective cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. journal of clinical oncology, 2010, 28(18):3015- 3022.[2]. chipumuro e., marco e., christensen c.l., et al. cdk7 inhibition suppresses super-enhancer-linked oncogenic transcription in mycn-driven cancer. cell, 2014, 159:1-14.[3]. meng h., jin y.m., liu h., et al. sns-032 inhibits mtorc1/mtorc2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against akt. journal of hematology & oncology, 2013, 6:18.[4]. chen r., wierda w.g., chubb s., et al. mechanism of action of sns032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. blood, 2009, 113(19):4637-4645.

InChI:InChI=1/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)

Upstream product

• 76779-98-1 1-azido-3,3-dimethyl-2-butanone 
• 13547-70-1 1-chloro-3,3-dimethyl-butan-2-one 
• 333389-44-9 α-N-2-(chloroacetylamino)pinacolone 
• 224436-97-9 2-amino-5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-thiazole 
• 224441-73-0 2-(chloromethyl)-5-t-butyloxazole 
• 33119-72-1 1-amino-3,3-dimethylbutan-2-one hydrochloride 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 5469-26-1 1-Bromopinacolon 
• 498-94-2 isonipecotic acid 
• 345629-23-4 tert-butyl 4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-carbamoyl)piperidine-1-carboxylate 

Relevant articles and documents

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

-